and children the IgG anti-polysaccharide antibodies predominantly reside in the IgGl subclass (4, 5) . The mechanisms that determine the localization of anti-polysaccharide antibodies in the IgG2 subclass are poorly understood. In childhood, S. pneumoniae is the primary pathogen involved in bacterial respiratory tract infections such as otitis media acuta and sinusitis (6, 7) . In view of the increased susceptibility to infections with encapsulated bacteria such as S. pneumoniae, observed in children or in IgG2-deficient individuals, IgGl anti-carbohydrate antibodies may be less protective compared with IgG2 antibodies (4, 8) .
Some children (older than 2 y) remain highly susceptible to infections with S. pneumoniae, despite normal serum Ig levels, including IgG subclasses. They suffer from recurrent acute otitis media and sinopulmonary infections. We previously described deficient anti-pneumococcal antibody responses in a group of children with frequent recurrent bacterial upper respiratory tract infections (9) . However, we (and others) found
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that only 10-15% of these infection-prone children had low to absent anti-polysaccharide antibodies (9, 10) . We now investigated IgM, IgG1, IgG2, and IgA responses to pneumococcal vaccine in a group of 46 children with normal serum Ig levels and recurrent bacterial respiratory tract infections. In addition, anti-pneumococcal antibody responses of 15 patients with humoral immunodeficiency (such as selective IgA or IgG2 deficiency) are described.
METHODS

Patients.
Sixty-one patients aged 1.7-17.1 y were included in the study (Table 1) . Between 1989 and 1990 the patients were referred to the department of immunology of our hospital by their pediatrician or otolaryngologist for immunologic evaluation. All patients suffered from recurrent acute otitis medial otorrhea and recurrent sinusitis with purulent nasal discharge, foul smelling breath, and coughing for at least six to eight episodes per year (Table I) . During each episode the children had a fever of >38S°C for at least 24 h and general malaise. The patients finally improved only after antibiotic treatment and often needed prolonged courses of antibiotics. Some patients had documented invasive infections with S. pneumoniae or Hib (Table 1) . Patients with allergy as the major source of symptoms were excluded from the study. Patients with anatomic abnormalities or recognized disease entities such as cystic fibrosis, granulocytopenia, or complement deficiency were also excluded from the study.
Parental consent was obtained for an intramuscular immunization with 23-valent pneumococcal vaccine (Pneumovax; Merck, Sharp and Dohme, Haarlem, The Netherlands) containing 25 p g of 23 pneumococcal serotypes (1, 2, 3,4, 5, 6B, 7F,  8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20 , 22F, 23F, and 33F). Serum was obtained before and 14 d after vaccination and stored at -80°C until use.
Determination of serum Zg. Concentrations of IgM, IgG subclasses, and IgA were determined on two or more occasions by radial immunodiffusion. A range of 2 SD above to 2 SD below the mean for age was considered normal (11, 12) . Diphtheria and tetanus toxoid antibodies were determined as previously described (13) . A titer of less than 0.1 UImL for a fully immunized child was considered below normal (13) . Anti-blood group isohemagglutinins anti-A and anti-B were determined by standard methods. Antibody titers below 1:16 after 2 y of age were considered below normal. IgE was determined by ELISA.
Anti-pneumococcal antibody assay. Serum IgM, IgGl, IgG2, and IgA anti-pneumococcal antibodies to five pneumococcal serotypes (3, 4, 6A, 9N, and 19F) were quantified by ELISA before and 14 d after immunization with pneumococcal vaccine. Pre-and postimmunization serum samples from individuals were analyzed simultaneously (and in duplicate). All serum samples were preincubated overnight, with excess free CPS to remove anti-CPS antibodies (14) . A standard serum from a normal nonvaccinated adult was included in every ELISA run as a control. If the results of the control deviated by more than 10% from the mean, the whole ELISA was repeated. Microtiter plates (Greiner Labortechnik, Langerthal, Germany) were coated with pneumococcal capsular polysaccharides (American Type Culture Collection, Rockville, MD, 10 pg/ mL) in saline solution at 37OC, overnight. Subsequently, plates were washed (PBS, Tween 20, 0.05%, vol/vol), and incubated for 2 h at 37°C with serial dilutions of serum samples in PBS, 0.05% Tween 20, 1% bovine serum albumin (vol/vol). After washing (PBS-Tween-BSA), the plates were incubated for 2 h (37"C), with alkaline phosphatase-labeled goat anti-human IgM (2492, lot no. 5701), goat anti-human IgA (2491, lot no. 2601) antibodies (Tago, Inc., Burlingame, CA), peroxidaselabeled, subclass-specific murine anti-human IgGl (MH161-lME, lot no. 1328-04H01), or IgG2 (MH162-lME, lot no. 1329-05-01) monoclonals (Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam, The Netherlands). After washing and incubation with enzyme substrate for 10-20 min, 37"C, absorbance was read using a Titertek Multiscan (Flow Laboratories, Irvine, CA). The antibody concentrations in the serum samples were calculated by comparison with a human hyperimmune plasma pool (15) . This plasma pool contains 2648 ng of Ab N/mL for serotype 3; 1196 ng Ab NImL for serotype 4; 539 ng Ab NImL for group 6; 927 ng Ab NlmL for group 9 and 440 ng Ab NImL for group 19 as determined by RIA (15) .
Ideally, the definition of normal responses at different ages requires a representative group of healthy age-matched controls, immunized with pneumococcal vaccine. However, at the present no such group is available, nor are normal IgM, IgG1, IgG2, and IgA values after pneumococcal vaccination both in adults and children. For this reason, we have chosen to express antibody concentrations of patient samples relative to the reference adult hyperimmune plasma pool of 112 healthy adults immunized with pneumococcal vaccine (15) . The reference pool was assigned 100 U/mL (100%) for each serotype.
Evaluation of antibody responses to pneumococcal polysaccharides. The fold increase was calculated by dividing the postvaccination titer by the preimmunization titer. The response to an individual pneumococcal serotype was considered 814 SANDERS ET AL. low to absent if the postimmunization titer remained below 20 UlmL (i.e. <20% of the antibody concentration in the reference hyperimmune plasma pool of healthy adult volunteers) (9, 15) .
Statistical analysis. Pearsson and Spearman rank correlation coefficients were determined between age and pre-and postimmunization levels, and between Ig isotype specific antipneumococcal responses and corresponding serum levels of total IgM, IgG1, IgG2, and IgA. Because anti-pneumococcal antibody distributions varied widely between individuals, log transformed values were used in calculations of means of responses to each pneumococcal serotype (geometric mean 2 SEM).
RESULTS
Patients serum Zg. Forty-six patients had serum IgM, IgG, IgA, and IgG subclass levels within or above the normal range of our laboratory (mean for age values -+ 2 SD). These patients were designated as group I. Three patients of group I had strongly elevated total serum IgG, and two of them also had elevated total IgM and/or IgA serum levels. One of these patients had bronchiectasis (patient 1.45 of group I; Fig. 1 ). Although the IgGl and IgG2 subclass levels of group I were within the normal range, 15/46 children (30%) had serum IgG2 levels between 1 and 2 SD below the mean for age. Two patients had elevated IgE levels. Bronchial hyperreactivity was present in 6/46 patients (13%).
Fifteen patients had various forms of dysimmunoglobulinemia such as IgA or IgG2 deficiency (Table 2 ). These patients were designated as group 11. One of them (patient 11.2 of group 11; Fig, 2 and Table 2 ) had mildly elevated IgE and recurrent wheezing. Three additional patients (20%) had bronchial hyperreactivity without atopic disease.
Patients clinical history. The clinical characteristics of the two groups of patients are presented in Table 1 . In most patients, the history of respiratory tract infections typically started between 6 and 12 mo of age. The mean age of the 46 patients of group I was younger than that of group 11 (4.4 versus 6.3 y). A family history of an immune deficiency disorder was present in a boy of group I (patient 1.21; Fig. I ), who had an older brother and sister with IgG2-IgG4 deficiency and selective antibody deficiency to polysaccharide antigens (patients 11.9 and 11.10; Table 2 and Fig. 2 ). One girl (patient 1.15 of group I; Fig. 1 ) had Fallot's tetralogy.
All patients suffered from frequent recurrent otitis media acuta/otorrhea and recurrent sinusitis. Surgical procedures such as adenoidectomy, myringotomies with polyethylene tube placement, mastoidectomy, lavage, or antrostomy of the maxillary sinuses had been performed in the majority of the patients (Table 1 ). Pneumonia, confirmed by chest radiography, was observed in 39% of patients of group I but more often in group I1 (73%, Kruskall-Wallis p = 0.014). Invasive infections with S. pneumoniae or Hib were similar in both groups (Table 1) .
Zsohemagglutinins, anti-tetanus and anti-diphtheria toxoid antibodies. All patients of both groups had normal anti-tetanus and anti-diphtheria antibody titers according to their immuni- . Antibody titers that remained below 30 UlmL (hatched), 20 UlmL (shaded), and 10 UImL (black) to four to five of five pneumococcal serotypes are shown. Patients are numbered consecutively according to age; patient 1.1 was 1.7 y and patient 1.46 was 14.7 y. An asterisk designates patients who were described as nonresponders in a previous article (9) . zation status (results not shown) (9) . Two patients of group I (1.21 and 1.46; Fig. 1 ) who were both un-responsive to pneumococcal vaccine had low isohemagglutinin levels. Six of the 15 patients of group I1 (11.2, 11.9, 11.10, 11.11, 11.12, and 11.15; Table 2 and Fig. 2 ) had low isohemagglutinin levels. Five of Patients are numbered consecutively according to age; patient 11.1 was 2.3 y and patient 11.15 was 17.1 y. A diagonal crossed box indicates a deficiency of corresponding isotype or subclass. An asterisk designates patients who were described as nonresponders in a previous article (9).
these six patients were unresponsive to pneumococcal vaccination (Fig. 2) . During follow-up, the IgA deficiency of one patient (patient 11.1; Table 2 and Fig. 2 ) turned out to be transient. When she was 4 y of age, her IgA was within normal levels and so were her isohemagglutinin levels. Two patients of group I1 (11.13 and 11.14; Table 2 and Fig. 2 ) had blood group AB. Anti-pneumococcal antibody levels. Ig isotype specific IgM, IgG1, IgG2, and IgA antibody responses to five pneumococcal serotypes were measured. We tested three strong immunogenic serotypes (3, 4, and 9N), one intermediate and age-dependent serotype (19F), and a weak immunogenic serotype (6A) (16) . These five serotypes frequently cause childhood infections with S. pneumoniae (17) . Geometric mean preand postimmunization antibody titers (geometric mean 2 SEM), and the mean fold increase of both groups of patients are presented in Figure 3 . No significant correlations between age and pre-and postimmunization antibody levels were observed ( p > 0.05). There was no relation between IgM, IgG1, IgG2, and IgA isotype-specific anti-pneumococcal antibody responses and total serum levels of these isotypes (Pearsson and Spearman rank correlation coefficients). Specifically, we could not confirm the observation of Siber et al. (18) who found a relation between IgG2 serum levels and the mean antibody responses to pneumococcal antigens as well as the Hib capsular antigen, as determined by RIA.
In the patients with normal serum Ig, the mean preimmunization anti-pneumococcal IgM levels were between 20 and 50 U/mL compared with the adult hyperimmune reference pool (Fig. 3) . The mean fold increase for IgM was 2.0-2.6 for all five serotypes, including both strong and weak immunogenic types. Mean postimmunization IgM levels above 100 U/mL were observed for serotype 3, and the other four serotypes reached levels between 60 and 90 U/mL. Thus, postimmunization anti-pneumococcal IgM levels of group I patients in general were comparable to the adult reference pool.
The mean postimmunization anti-pneumococcal IgGl levels were higher than those observed in the adult control plasma pool for the strong immunogenic types; IgGl reached levels above 200 U/mL for type 3 and more than 100 U/mL for types 4 and 9N. However, in case of weak immunogenic serotypes, the mean IgGl levels remained below the adult control pool (25 and 50 U/mL for 6A and 19F, respectively).
The most striking finding of this study were the very low to absent IgG2 anti-polysaccharide antibody titers in the patient population, despite normal total serum IgG2 levels; the mean anti-pneumococcal IgG2 levels remained <20 U/mL even for the strong immunogenic serotypes (3, 4, and 9N), and <5 U/mL (often undetectable) for 6A and 19F.
IgA antibodies were low to absent in preimmunization sera. However, after vaccination, considerable increases were observed; more than a 10-fold increase was observed for types 4 and 9N, a 7-fold increase for types 6A and 9N, and 5-fold for type 3, which showed the highest preimmunization level. The mean postimmunization IgA levels, however, remained well 816 SANDERS ET AL. below the adult reference pool: about 50 U/mL for types 3 and 9N, 30-50 U/mL for types 4, and 19F and low (20 U/mL) for type 6A.
In conclusion, in children with recurrent infections and normal serum Ig levels, anti-pneumococcal IgM and IgGl responses seem to be comparable to the adult reference pool (at least for the well immunogenic serotypes), whereas IgA and IgG2 antibody titers remained low.
In the patients of group I1 with dysimmunoglobulinemia, the mean postimmunization levels were mostly lower than group I (Fig. 3) , due to the presence of several patients who had low to absent antibody titers of all isotypes (see also Fig. 2 , as discussed below). Obviously, in a group of patients with either IgA or IgG2 deficiency, mean anti-pneumococcal IgA and IgG2 levels remained low.
Zsotype and ZgG subclass responses of individual patients of group I. We previously described five patients with normal serum Ig levels and a defective anti-pneumococcal antibody response (defined as antibody titers of <20 U/mL for five to seven out of seven tested pneumococcal serotypes) (9) . These patients are included in group I (patients 1.1, 1.13, 1.15, 1.21, and 1.46; Fig. 1 ). Analysis of Ig isotype and IgG subclass distribution of anti-pneumococcal antibodies revealed that two of these five patients (1.21 and 1.46; Fig. 1 ) failed to generate responses in all Ig isotypes to all five serotypes. In the other three patients (1.1,1.13, and 1.15; Fig. I ), the postimmunization IgG2 and IgA antibody levels remained <20 U/mL, and IgM responses remained below 30 U/mL for all pneumococcal serotypes that were evaluated (Fig. 1) . We now found that, apart from these five patients, in an additional 15 patients, in which the total anti-pneumococcal antibody response as such was not defective, the postimmunization IgG2 anti-pneumococcal antibody levels remained low to absent (<20 U/mL). In four of these 15 patients, anti-pneumococcal IgA antibody levels also remained <20 U/mL, whereas one patient (patient 1.40; Fig. 1 ) also had IgGl levels <20 U/mL. This patient, who was previously described as a responder patient, showed only (high) IgM responses. Two other patients (1.11 and 1.33; Fig. 1 ) had a selective IgA anti-pneumococcal polysaccharide deficiency.
Zsotype and ZgG subclass responses of individual patients of group ZZ. As expected, deficient anti-pneumococcal responses were observed frequently in patients of group I1 (Fig.  2) . Six of the 15 patients (40%) had postimmunization antipneumococcal antibody levels of <20 U/mL for all isotypes. Five of these six patients have already been described as nonresponders to pneumococcal vaccine in a former study (patients 11.7, 11.9, 11.10, 11.13, and 11.15; Fig. 2 and Table 2 ) (9). A sixth patient (patient 11.12; Fig. 2 and Table 2 ) with IgG2 deficiency has not been described before. This boy suffered from the invasive infections pneumococcal arthritis, bacteremia, and streptococcal endocarditis (apart from his chronic recurrent otorrhea and sinubronchitis). The IgM responses of the remaining nine patients were in the same range compared with group I (data not shown). Of note is patient 11.11 of group I1 ( Table 2 and Fig. 2) , previously described as hypogammaglobulinemic but responding to pneumococcal vaccine (9) . The anti-pneumococcal antibody response was restricted to IgM antibodies, therefore resembling that patient 1.40 of group I as described above (Fig. 1) . IgM responses in hypogammaglobulinemic patients have previously been observed (19) . IgGl anti-pneumococcal levels in the "responder" patients of group I1 were comparable to those of group I (data not shown). All but one patient (patient 11.4; Fig. 2 and Table 2 ) failed to make IgG2 anti-carbohydrate antibodies. This patient was IgA-and IgG3-deficient, but had high serum IgG2 levels ( Table 2) . A deficient IgA anti-polysaccharide response was found in all dysimmunoglobulinemic patients of group 11, except for the two patients whose serum IgA level increased toward normal levels during follow-up and whose IgA deficiency turned out to be transient (patients 11.2 and 11.6; Fig. 2 and Table 2 ), and a third patient with low IgG2 and IgG3 levels (patient 11.1; Fig.  2 and Table 2 ). Two siblings with nondetectable serum IgG2 but normal serum IgA levels, however, failed to make IgA anti-polysaccharide antibodies upon immunization with pneumococcal vaccine (patients 11.3 and 11.8; Fig. 2 and Table 2 ).
DISCUSSION
The effective removal of (encapsulated) bacteria requires phagocytosis of opsonized bacteria, a process that depends on the efficient interaction between anticapsular antibodies and Fc receptors, as well as complement and complement receptors (20) . Specific antibodies to the bacterial capsular polysaccharides play a crucial role in this process, and their presence, as a result from primary infection, vaccination or crossimmunization, may prevent reinfection.
The immune response to pneumococcal polysaccharides normally involves IgM, IgG1, IgG2, and IgA Ig isotypes. We found that, in a childhood population with frequent infections with encapsulated bacteria such as S. pneumoniae, aberrant responses to pneumococcal vaccine were frequently observed. Although low to absent antibody responses of all isotypes were observed in only 2/46 (4%) infection-prone patients with normal serum Ig, low to absent anti-pneumococcal IgG2 (20146, 43%) and/or IgA responses (10146, 22%) were common. We did not investigate the G2m(23) allotypes of the patients in relation to the IgG2 responses (21) . However, in previous studies, low IgG2 levels in infection-prone children were not related to the G2m(23) allotype (22) .
In contrast to patients with normal serum Ig levels, aberrant responses to pneumococcal vaccine were frequently observed in infection prone patients with humoral immunodeficiency like IgA and/or IgG subclass deficiency; absent responses of all isotypes were observed in 6/15 patients (40%). These patients and their clinical history have been described previously (9) . Furthermore, almost all (14115) patients with humoral immunodeficiency failed to show IgG2 anti-pneumococcal responses. IgA responses were absent in 12/15 (80%) of the patients, with the exception of one patient with low IgG2 and IgG3 levels, and two patients whose IgA deficiency turned out to be transient. The observed frequencies of absent antibody responses in 4% of infection-prone patients with normal serum Ig, and 40% of patients with IgA and/or IgG subclass deficiency are similar to those observed in a recent study by Gross et al. (23) . Furthermore, the results of our study indicate that, next to the observation that some patients lack antipneumococcal antibody responses of all isotypes, an inability to make IgG2 or IgA antibodies also appears to define a clinical entity of high susceptibility for infections with S. pneumoniae. This, despite the fact that these patients do have IgGl (and IgM responses).
Although the seemingly superiority of IgG2 anti-pneumococcal carbohydrate antibodies compared with IgGl antibodies remains to be fully explained, clinical observations support the hypothesis of possible advantages of anti-carbohydrate antibodies localized in the IgG2 subclass (3, 8) . For instance, otitis-prone children have similar IgGl anti-pneumococcal antibody levels compared with age-matched controls, but lower IgG2 levels to some pneumococcal polysaccharides (8) . Furthermore, IgGl and IgG2 anti-carbohydrate antibodies may display different avidity for polysaccharide antigens (24) . For example, the relative avidity of IgG2 antibodies for pneumococcal serotype 3 was shown to be superior to the IgGl subclass (24) . Avidity of a given antibody, rather than its concentration, may determine clinical protection from disease (25, 26) .
Until recently, it was emphasized that IgGl is much more effective in activating the classical complement pathway compared with IgG2 (27) . IgG2 activation of the classical pathway is variable. However, IgG2 seems to be superior to other IgG isotypes in activation of the alternative pathway, in the presence of high epitope density and antibodylantigen equivalence or antibody excess (28, 29) . High antigen concentrations and epitope density are typical for repetitive capsular polysaccharide antigens present on the surface of encapsulated bacteria.
In (opsono)phagocytic assays, both IgGl and IgG2 antibodies are effective (30, 31) . However, in some studies, using encapsulated bacteria, the opsonic capacity of IgGl anticapsular antibodies were superior to IgG2 (phagocytosis of Hib) (30, 32) , whereas in others IgG2 antibodies were found to be superior to IgGl (S. pneumoniae and group B Streptococcus type 111) (31, 33) . In a study of Chudwin et al. (34) , opsonic activity for S. pneumoniae correlated with IgG2 antibody concentrations rather than with IgG1. Phagocytosis of bacteria like S. pneumoniae (31) or type I11 Streptococcus group B (33) may be more dependent on IgG2 compared with Hib (30, 32) . It was also observed that efficient opsonization of S. pneumoniae by IgGl requires complement, whereas IgG2 may facilitate phagocytosis independent of complement and is mediated by the Fc part of the molecule (31) .
The fact remains that IgGl interacts better with Fc receptors for IgG (Fcy-R) than IgG2 (35) . However, in most studies on IgG1-and IgG2-mediated phagocytosis of bacteria by granulocytes, the allotype of the Fc receptor for IgG2 expressed by the granulocytes (FcyIIa, CD32), has not been taken into account (30, 31, 33) . The two allotypes of the Fc receptor for IgG2 on phagocytic cells differ in the interaction with complexed IgG2 (35) and in phagocytic capacities (32, 36) . Consequently, the results of phagocytic assays in the past, comparing anti-polysaccharide I g G l and IgG2-mediated phagocytosis of encapsulated bacteria, may be largely biased by the (at the time unknown) FcyRIIa phenotype of the donor granulocytes used in the assay.
Apart from deficient anti-pneumococcal IgG2 responses, deficient serum IgA responses were frequently observed. In preimmunization sera, anti-pneumococcal IgA levels are low to undetectable. Upon vaccination, large increases of antipneumococcal IgA antibodies were observed. Although we did not investigate IgA subclasses, the serum IgA responses to bacterial polysaccharide antigens (S. pneumoniae, Hib, and Neisseria meningitidis) are reported to be primarily polymeric and of the IgA2 isotype (37) . Studies on the functional role of serum IgA provided evidence that IgA has opsonizing qualities and stimulates phagocytosis of bacteria (38, 39) . Stewart and Kerr (40) report that IgA induces a respiratory burst via the Fc receptor for IgA, Fca, which was found to be even greater than the burst elicited by an equivalent concentration of IgG. Furthermore, IgA seems to be the best activator of the alternative complement pathway, which was found to be independent of epitope density and antigenJantibody ratio (28) .
In contrast to IgG and IgA responses, IgM responses were relatively normal in most patients, irrespective of the immunogenicity of the pneumococcal serotype. Apart from 5/46 patients of group I and 6/15 patients of group 11, all patients showed anti-pneumococcal IgM levels to both strongly and weakly immunogenic serotypes. The function of IgM may be mainly bactericidal via complement-mediated lysis, but IgM is probably less effective than IgG in both opsonization (Hib) (41, 42) and protection from pneumococcal disease (31, 43) . Several investigators failed to demonstrate a significant correlation between IgM anti-pneumococcal antibodies and opsonic activity (31, 43) The frequent combination of low IgG2 and IgA antipolysaccharide antibody responses in childhood patients with recurrent bacterial infections suggests a shared common underlying mechanism in the regulation of expression of the heavy chain genes. The low IgG2 and IgA responses to pneumococcal vaccine may be due to a delay of these latematurating isotypes. Long-term follow-up is necessary to distinguish patient, whose susceptibility is related to an as yet nonovert immunodeficiency, and those in whom low IgA and IgG2 responses may present a maturational delay of antibody formation (9) . Additional evaluation with other polysaccharide vaccines, polysaccharide conjugate vaccines, and in vitro studies of lymphocytes as described by Shackelford et al. (22) may be helpful. Furthermore, in view of the newly developed pneumococcal conjugate vaccines, induction of IgG2 antipneumococcal antibody production may be possible in the future and provide optimal clinical protection against pneumococcal disease in childhood.
